Continuous Glucose Monitoring for Diabetes

This trial investigates a new version of a continuous glucose monitoring device, the ROME GS System, for people with diabetes. The goal is to confirm that changes to the device do not impact its safety or performance compared to an existing model. This trial is particularly suited for individuals who have managed diabetes for over a year and have no history of severe hypoglycemia or other significant health complications. Participants should be willing to wear the device and adhere to the study's guidelines. As an unphased trial, this study offers participants the chance to contribute to advancements in diabetes management technology.

The trial does not specify if you need to stop taking your current medications, but it does exclude people who are currently receiving certain treatments like immunosuppressants, chemotherapy, and some blood thinners. It's best to discuss your specific medications with the trial team.

Research has shown that the ROME GS System, a device for continuous blood sugar monitoring, is generally safe. In one study, 97% of the sensors functioned for a full year, demonstrating durability. The sensors also accurately detected blood sugar levels, with a 96.6% success rate at lower levels and 97.9% at higher levels.

Reports of minor skin irritation were few, indicating good tolerance among users. The FDA has already approved the Eversense 365, a similar device, which boosts confidence in the ROME GS System's safety. This approval confirms it meets safety standards for monitoring glucose levels in adults with diabetes.

Unlike traditional glucose monitoring methods, the ROME GS System offers continuous glucose monitoring for diabetes management. This system is unique because it provides real-time glucose readings throughout the day and night, eliminating the need for frequent finger pricks. Researchers are excited about this treatment as it not only improves convenience and comfort for users but also allows for better glucose management by providing comprehensive data on glucose trends and patterns. This has the potential to significantly enhance diabetes care and improve overall health outcomes.

Research has shown that the Eversense 365 Continuous Glucose Monitoring (CGM) System is highly accurate, detecting low blood sugar levels 96.6% of the time and high blood sugar levels 97.9% of the time. Most sensors functioned effectively for a full year, and real-world evidence indicates consistent performance over time. In this trial, researchers are testing the ROME GS System as a separate treatment arm to ensure it achieves this level of performance without safety concerns.¹²⁶⁷⁸